CERO THERAPEUTICS HOLDINGS I (CERO) Stock Price & Overview
NASDAQ:CERO • US71902K4022
Current stock price
The current stock price of CERO is 0.0951 USD. Today CERO is down by -94.69%. In the past month the price decreased by -98.24%. In the past year, price decreased by -99.94%.
CERO Key Statistics
- Market Cap
- 177.837K
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -223.77
- Dividend Yield
- N/A
CERO Stock Performance
CERO Stock Chart
CERO Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to CERO. When comparing the yearly performance of all stocks, CERO is a bad performer in the overall market: 99.98% of all stocks are doing better.
CERO Earnings
CERO Forecast & Estimates
8 analysts have analysed CERO and the average price target is 22.95 USD. This implies a price increase of 24032.49% is expected in the next year compared to the current price of 0.0951.
CERO Groups
Sector & Classification
CERO Financial Highlights
Over the last trailing twelve months CERO reported a non-GAAP Earnings per Share(EPS) of -223.77. The EPS increased by 63.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -675.76% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CERO Ownership
CERO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.55 | 354.636B | ||
| AMGN | AMGEN INC | 15.27 | 186.69B | ||
| GILD | GILEAD SCIENCES INC | 15.12 | 164.958B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.34 | 111.326B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.34 | 78.928B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.97 | 41.441B | ||
| INSM | INSMED INC | N/A | 31.186B | ||
| NTRA | NATERA INC | N/A | 29.449B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.041B | ||
| BIIB | BIOGEN INC | 11.65 | 27.895B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.6 | 25.171B | ||
| MRNA | MODERNA INC | N/A | 22.05B | ||
| INCY | INCYTE CORP | 12.33 | 19.252B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CERO
Company Profile
CERo Therapeutics Holdings, Inc. is an immunotherapy company, which engages in development of engineered T cell therapeutics for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 8 full-time employees. The company went IPO on 2021-10-06. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is designed to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what the Company refers to as Chimeric Engulfment Receptor T cells (CER-T). Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand. The firm is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies.
Company Info
IPO: 2021-10-06
CERO THERAPEUTICS HOLDINGS I
201 Haskins Way, Suite 230
South San Francisco CALIFORNIA US
Employees: 8
Phone: 6504072376
CERO THERAPEUTICS HOLDINGS I / CERO FAQ
What does CERO do?
CERo Therapeutics Holdings, Inc. is an immunotherapy company, which engages in development of engineered T cell therapeutics for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 8 full-time employees. The company went IPO on 2021-10-06. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is designed to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what the Company refers to as Chimeric Engulfment Receptor T cells (CER-T). Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand. The firm is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies.
Can you provide the latest stock price for CERO THERAPEUTICS HOLDINGS I?
The current stock price of CERO is 0.0951 USD. The price decreased by -94.69% in the last trading session.
Does CERO THERAPEUTICS HOLDINGS I pay dividends?
CERO does not pay a dividend.
How is the ChartMill rating for CERO THERAPEUTICS HOLDINGS I?
CERO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Should I buy CERO stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CERO.
What is the employee count for CERO stock?
CERO THERAPEUTICS HOLDINGS I (CERO) currently has 8 employees.
What is CERO THERAPEUTICS HOLDINGS I worth?
CERO THERAPEUTICS HOLDINGS I (CERO) has a market capitalization of 177.84K USD. This makes CERO a Nano Cap stock.